The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1L1WGD     2-benzo[1,3]dioxol-5-yl-N- methyl-propan-1...

Synonyms: A825934, 54946-52-0
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of 3,4-methylenedioxymethamphetamine


Psychiatry related information on 3,4-methylenedioxymethamphetamine


High impact information on 3,4-methylenedioxymethamphetamine


Chemical compound and disease context of 3,4-methylenedioxymethamphetamine


Biological context of 3,4-methylenedioxymethamphetamine


Anatomical context of 3,4-methylenedioxymethamphetamine


Associations of 3,4-methylenedioxymethamphetamine with other chemical compounds


Gene context of 3,4-methylenedioxymethamphetamine


Analytical, diagnostic and therapeutic context of 3,4-methylenedioxymethamphetamine


  1. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Henry, J.A., Jeffreys, K.J., Dawling, S. Lancet (1992) [Pubmed]
  2. Protection against 3,4-methylenedioxymethamphetamine-induced neurodegeneration produced by glutathione depletion in rats is mediated by attenuation of hyperthermia. O'Shea, E., Easton, N., Fry, J.R., Green, A.R., Marsden, C.A. J. Neurochem. (2002) [Pubmed]
  3. The role of mitochondrial uncoupling in 3,4-methylenedioxymethamphetamine-mediated skeletal muscle hyperthermia and rhabdomyolysis. Rusyniak, D.E., Tandy, S.L., Hekmatyar, S.K., Mills, E., Smith, D.J., Bansal, N., MacLellan, D., Harper, M.E., Sprague, J.E. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  4. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("ecstasy"). Fiege, M., Wappler, F., Weisshorn, R., Gerbershagen, M.U., Menge, M., Schulte Am Esch, J. Anesthesiology (2003) [Pubmed]
  5. The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain. Stephenson, C.P., Hunt, G.E., Topple, A.N., McGregor, I.S. Neuroscience (1999) [Pubmed]
  6. Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. Cami, J., Farré, M., Mas, M., Roset, P.N., Poudevida, S., Mas, A., San, L., de la Torre, R. Journal of clinical psychopharmacology. (2000) [Pubmed]
  7. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy'). McGuire, P.K., Cope, H., Fahy, T.A. The British journal of psychiatry : the journal of mental science. (1994) [Pubmed]
  8. Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Kuypers, K.P., Ramaekers, J.G. Psychopharmacology (Berl.) (2007) [Pubmed]
  9. Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test. Ando, R.D., Benko, A., Ferrington, L., Kirilly, E., Kelly, P.A., Bagdy, G. Neuropharmacology (2006) [Pubmed]
  10. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Green, A.R., Mechan, A.O., Elliott, J.M., O'Shea, E., Colado, M.I. Pharmacol. Rev. (2003) [Pubmed]
  11. Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Roiser, J.P., Cook, L.J., Cooper, J.D., Rubinsztein, D.C., Sahakian, B.J. The American journal of psychiatry. (2005) [Pubmed]
  12. (+) 3,4-methylenedioxymethamphetamine ('ecstasy') transiently increases striatal 5-HT1B binding sites without altering 5-HT1B mRNA in rat brain. Sexton, T.J., McEvoy, C., Neumaier, J.F. Mol. Psychiatry (1999) [Pubmed]
  13. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Bunzow, J.R., Sonders, M.S., Arttamangkul, S., Harrison, L.M., Zhang, G., Quigley, D.I., Darland, T., Suchland, K.L., Pasumamula, S., Kennedy, J.L., Olson, S.B., Magenis, R.E., Amara, S.G., Grandy, D.K. Mol. Pharmacol. (2001) [Pubmed]
  14. Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Walker, Q.D., Williams, C.N., Jotwani, R.P., Waller, S.T., Francis, R., Kuhn, C.M. Psychopharmacology (Berl.) (2007) [Pubmed]
  15. Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. Wallace, T.L., Gudelsky, G.A., Vorhees, C.V. Psychopharmacology (Berl.) (2001) [Pubmed]
  16. Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Crean, R.D., Davis, S.A., Von Huben, S.N., Lay, C.C., Katner, S.N., Taffe, M.A. Neuroscience (2006) [Pubmed]
  17. Reinforcement schedule effects in rats trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or cocaine. Kueh, D., Baker, L.E. Psychopharmacology (Berl.) (2007) [Pubmed]
  18. Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia. Rusyniak, D.E., Banks, M.L., Mills, E.M., Sprague, J.E. Anesthesiology (2004) [Pubmed]
  19. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Bengel, D., Murphy, D.L., Andrews, A.M., Wichems, C.H., Feltner, D., Heils, A., Mössner, R., Westphal, H., Lesch, K.P. Mol. Pharmacol. (1998) [Pubmed]
  20. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). McKenna, D.J., Peroutka, S.J. J. Neurochem. (1990) [Pubmed]
  21. Site-specific regulation of corticosteroid and serotonin receptor subtype gene expression in the rat hippocampus following 3,4-methylenedioxymethamphetamine: role of corticosterone and serotonin. Yau, J.L., Noble, J., Seckl, J.R. Neuroscience (1997) [Pubmed]
  22. Clozapine reverses increased brown adipose tissue thermogenesis induced by 3,4-methylenedioxymethamphetamine and by cold exposure in conscious rats. Blessing, W.W., Zilm, A., Ootsuka, Y. Neuroscience (2006) [Pubmed]
  23. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. Hernández-López, C., Farré, M., Roset, P.N., Menoyo, E., Pizarro, N., Ortuño, J., Torrens, M., Camí, J., de La Torre, R. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  24. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. Callaghan, P.D., Owens, W.A., Javors, M.A., Sanchez, T.A., Jones, D.J., Irvine, R.J., Daws, L.C. J. Neurochem. (2007) [Pubmed]
  25. 3,4-Methylenedioxymethamphetamine increases pro-interleukin-1beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: role of interleukin-1beta in neurotoxicity. O'Shea, E., Sanchez, V., Orio, L., Escobedo, I., Green, A.R., Colado, M.I. Neuroscience (2005) [Pubmed]
  26. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine ("Ecstasy") on hepatic stellate cells. Montiel-Duarte, C., Ansorena, E., López-Zabalza, M.J., Cenarruzabeitia, E., Iraburu, M.J. Biochem. Pharmacol. (2004) [Pubmed]
  27. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Wilson, M.A., Ricaurte, G.A., Molliver, M.E. Neuroscience (1989) [Pubmed]
  28. Binge administration of 3,4-methylenedioxymethamphetamine ("ecstasy") impairs the survival of neural precursors in adult rat dentate gyrus. Hern??ndez-Rabaza, V., Dom??nguez-Escrib??, L., Barcia, J.A., Rosel, J.F., Romero, F.J., Garc??a-Verdugo, J.M., Canales, J.J. Neuropharmacology (2006) [Pubmed]
  29. Chiral separation of 3,4-methylenedioxymeth- amphetamine and related compounds in clandestine tablets and urine samples by capillary electrophoresis/fluorescence spectroscopy. Huang, Y.S., Liu, J.T., Lin, L.C., Lin, C.H. Electrophoresis (2003) [Pubmed]
  30. Panic disorder induced by large doses of 3,4-methylenedioxymethamphetamine resolved by paroxetine. Windhaber, J., Maierhofer, D., Dantendorfer, K. Journal of clinical psychopharmacology. (1998) [Pubmed]
  31. Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate. Nixdorf, W.L., Burrows, K.B., Gudelsky, G.A., Yamamoto, B.K. J. Neurochem. (2001) [Pubmed]
  32. DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). Fornai, F., Lenzi, P., Frenzilli, G., Gesi, M., Ferrucci, M., Lazzeri, G., Biagioni, F., Nigro, M., Falleni, A., Giusiani, M., Pellegrini, A., Blandini, F., Ruggieri, S., Paparelli, A. Psychopharmacology (Berl.) (2004) [Pubmed]
  33. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). Jayanthi, S., Ladenheim, B., Andrews, A.M., Cadet, J.L. Neuroscience (1999) [Pubmed]
  34. Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced toxicity to brain dopaminergic neurons. Xie, T., Tong, L., McCann, U.D., Yuan, J., Becker, K.G., Mechan, A.O., Cheadle, C., Donovan, D.M., Ricaurte, G.A. J. Neurosci. (2004) [Pubmed]
  35. Pharmacology: uncoupling the agony from ecstasy. Mills, E.M., Banks, M.L., Sprague, J.E., Finkel, T. Nature (2003) [Pubmed]
  36. Role of the 5-HT2 receptor in the methamphetamine-induced neurochemical alterations. Johnson, M., Sonsalla, P.K., Letter, A.A., Hanson, G.R., Gibb, J.W. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  37. Stacking and low-temperature technique in nonaqueous capillary electrophoresis for the analysis of 3,4-methylenedioxymethamphetamine. Tsai, C.H., Fang, C., Liu, J.T., Lin, C.H. Electrophoresis (2004) [Pubmed]
  38. Effects of ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Reneman, L., Majoie, C.B., Habraken, J.B., den Heeten, G.J. Radiology. (2001) [Pubmed]
  39. Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Hiramatsu, M., Cho, A.K. Neuropharmacology (1990) [Pubmed]
  40. Acute effects of 3,4-methylenedioxymethamphetamine on brain serotonin synthesis in the dog studied by positron emission tomography. Nishisawa, S., Mzengeza, S., Diksic, M. Neurochem. Int. (1999) [Pubmed]
  41. Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Marston, H.M., Reid, M.E., Lawrence, J.A., Olverman, H.J., Butcher, S.P. Psychopharmacology (Berl.) (1999) [Pubmed]
WikiGenes - Universities